The 2019 European Lung Cancer Congress (ELCC), held in Geneva, Switzerland, took place on the 10–13 April. Leading researchers from around the world showcased the latest research and developments in lung cancer.

ELCC 2019

10–13 April 2019 | Geneva, Switzerland

ELCC 2019

10–13 April 2019 | Geneva, Switzerland

The 2019 European Lung Cancer Congress (ELCC), held in Geneva, Switzerland, took place on the 10–13 April. Leading researchers from around the world showcased the latest research and developments in lung cancer.

Combining checkpoint inhibitors with chemotherapy for NSCLC 2:10
Combining checkpoint inhibitors with chemotherapy for NSCLC
Marina Garassino
I-O monotherapy for advanced NSCLC 1:23
I-O monotherapy for advanced NSCLC
Martin Reck
NSCLC: a treatment landscape in flux in the checkpoint inhibitor era 1:23
NSCLC: a treatment landscape in flux in the checkpoint inhibitor era
Martin Reck
Current treatment landscape for ALK-positive NSCLC 2:21
Current treatment landscape for ALK-positive NSCLC
Marina Garassino
IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC 1:31
IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC
Martin Reck
PACIFIC trial updates: durvalumab after chemotherapy in NSCLC 1:07
PACIFIC trial updates: durvalumab after chemotherapy in NSCLC
Marina Garassino
Treatment sequecing strategies in advanced NSCLC 1:14
Treatment sequecing strategies in advanced NSCLC
Martin Reck
Challenges in using ALK inhibitors 1:47
Challenges in using ALK inhibitors
Nicolas Girard
ALK-TKIs: targeted therapies for ALK-positive NSCLC 0:44
ALK-TKIs: targeted therapies for ALK-positive NSCLC
Antonio Passaro
Recent developments in radiotherapy for lung cancer 1:42
Recent developments in radiotherapy for lung cancer
Françoise Mornex
Managing oligometastatic NSCLC with thoracic irradiation 1:03
Managing oligometastatic NSCLC with thoracic irradiation
Françoise Mornex
The evolving role of the nurse in cancer therapy 1:50
The evolving role of the nurse in cancer therapy
Celia Diez de los Rios
Updates from the PROFILE 1001 study 2:05
Updates from the PROFILE 1001 study
Alice Tsang Shaw
Second-generation ALK inhibitors in ALK-positive NSCLC 0:42
Second-generation ALK inhibitors in ALK-positive NSCLC
Antonio Passaro
Prof. Kelly’s overview of the RECaN project 1:50
Prof. Kelly’s overview of the RECaN project
Daniel Kelly
The promise of stereotactic radiotherapy for oligometastases 1:16
The promise of stereotactic radiotherapy for oligometastases
Françoise Mornex
The content of VJOncology is intended for healthcare professionals